Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”

Detalles Bibliográficos
Autores principales: Wang, Yinhan, Huang, Yongfa, Yang, Huayu, Mao, Yilei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982347/
https://www.ncbi.nlm.nih.gov/pubmed/36872926
http://dx.doi.org/10.1159/000526804
_version_ 1784900311379345408
author Wang, Yinhan
Huang, Yongfa
Yang, Huayu
Mao, Yilei
author_facet Wang, Yinhan
Huang, Yongfa
Yang, Huayu
Mao, Yilei
author_sort Wang, Yinhan
collection PubMed
description
format Online
Article
Text
id pubmed-9982347
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-99823472023-03-04 Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma” Wang, Yinhan Huang, Yongfa Yang, Huayu Mao, Yilei Liver Cancer Letter to the Editor S. Karger AG 2022-08-31 /pmc/articles/PMC9982347/ /pubmed/36872926 http://dx.doi.org/10.1159/000526804 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
spellingShingle Letter to the Editor
Wang, Yinhan
Huang, Yongfa
Yang, Huayu
Mao, Yilei
Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”
title Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”
title_full Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”
title_fullStr Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”
title_full_unstemmed Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”
title_short Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”
title_sort letter regarding “impact of immune-related adverse events on efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma”
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982347/
https://www.ncbi.nlm.nih.gov/pubmed/36872926
http://dx.doi.org/10.1159/000526804
work_keys_str_mv AT wangyinhan letterregardingimpactofimmunerelatedadverseeventsonefficacyofimmunecheckpointinhibitorsinpatientswithadvancedhepatocellularcarcinoma
AT huangyongfa letterregardingimpactofimmunerelatedadverseeventsonefficacyofimmunecheckpointinhibitorsinpatientswithadvancedhepatocellularcarcinoma
AT yanghuayu letterregardingimpactofimmunerelatedadverseeventsonefficacyofimmunecheckpointinhibitorsinpatientswithadvancedhepatocellularcarcinoma
AT maoyilei letterregardingimpactofimmunerelatedadverseeventsonefficacyofimmunecheckpointinhibitorsinpatientswithadvancedhepatocellularcarcinoma

Ejemplares similares